PFE V3 technical snapshot
price=26.524999618530273 hma21=26.405213827818507 hma55=25.333468572827847 sma200=25.88552502632141
price=26.524999618530273 hma21=26.405213827818507 hma55=25.333468572827847 sma200=25.88552502632141
stock_deep_dive
PFE V3 technical snapshot
$PFE: evidence-based stock deep dive
PFIZER INC
CORE QUESTION
Can PFIZER INC's current revenue growth convert into earnings and cash flow before expectations outrun operating evidence? Sector-specific lens: Which regulatory, clinical or manufacturing milestone is the next measurable validation point?
WHAT CHANGED
• R&D expense year-over-year growth changed by +0.1 percentage points from the preceding reported quarter.
• Inventory year-over-year growth changed by -13.1 percentage points from the preceding reported quarter.
OPERATING EVIDENCE
• Revenue: $15.03B in Q2 2026; +2.6% YoY.
• Net income: $-248.00M in Q2 2026; -108.5% YoY.
• Diluted EPS: $-0.04 in Q2 2026; -107.8% YoY.
• R&D expense: $2.81B in Q2 2026; +13.2% YoY.
• Inventory: $9.95B in Q2 2026 period end; -14.8% YoY.
• Stock-based compensation: $272.00M in Q1 2026; +60.0% YoY.
EXPECTATIONS AND VALUATION
• trailing P/E 34.9x; forward P/E 9.2x; EV/EBITDA 8.1x; P/S 2.4x.
• Next-year Yahoo consensus snapshot for period ending 2027-12-31: EPS estimate $2.89 (25 analysts); revenue estimate $59.85B (25 analysts).
INSTITUTIONAL EVIDENCE
• 2026-07-08 — [COMPANY-SPECIFIC] Pfizer’s earnings guidance has room for an upward revision, but its pipeline remains the market’s focus (J.P. Morgan)
J.P. The report said Pfizer’s stock is currently valued at approximately 9 times projected 2027 earnings, making the valuation inexpensive, while several pipeline assets could add appeal to the long-term investment narrative.
However, the recent Phase 3 failure of sigvotatug vedotin in second-line or later non-small cell lung cancer represents a significant negative development and has reduced visibility into the development pipeline.
OFFICIAL COMPANY EVIDENCE
• 2026-08-04 — [SEC EXHIBIT 99.1] PFIZER INC filed an 8-K with the SEC — Exhibit 99.1 earnings release; reporting basis: mixed_reconciled.
• 2026-05-05 — [SEC EXHIBIT 99.1] PFIZER INC filed an 8-K with the SEC — Exhibit 99.1 earnings release; reporting basis: mixed_reconciled.
• 2026-08-04 — [SEC FILING NOTICE] PFIZER INC filed a 10-Q with the SEC.
• 2026-05-05 — [SEC FILING NOTICE] PFIZER INC filed a 10-Q with the SEC.
MARKET STRUCTURE
• Latest price $26.52; HMA21 $26.41; HMA55 $25.33; 200DMA $25.89.
EVIDENCE FOR
• Revenue changed +2.6% year over year in the latest comparable period.
• Price is above all three HMA21, HMA55 and 200DMA trend references.
• Forward P/E of 9.2x is below trailing P/E of 34.9x, implying expected earnings improvement.
• Official operating disclosure: EX-99 2 pfe-6282026xex99.htm EX-99 Document Exhibit 99 Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
■Focused Execution Drove 18% Operational Revenue Growth of Launched and Acquired Products(1) ■Advancing Robust Late-Stage Pipeline, with Several Key Pivotal Readouts
Expected Over Next 12 Months ■Announces Expansion of Productivity Enhancement Initiatives NEW YORK, Tuesday, August 4, 2026 — Pfizer Inc.
• Official operating disclosure: primarily due to pricing dynamics, including lower rebates and channel mix favorability, as well as higher demand globally; partially
offset by declines due to generic entry and price erosion in certain international markets; ■Padcev globally, up 23% operationally, driven primarily by increased market
share in first-line locally advanced or metastatic urothelial cancer (la/mUC), as well as launch uptake in the cisplatin-ineligible indication for muscle-invasive bladder
cancer; partially offset by a one-time favorable impact associated with transition to a wholesaler distribution model in the U
• Official operating disclosure: Phase 3 planning for atopic dermatitis is ongoing, with a pivotal study on track to start this year.
• Official operating disclosure: EX-99 2 pfe-3292026xex99.htm EX-99 Document Exhibit 99 g Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance ■Earnings
Driven by Focused Execution and 22% Op Revenue Growth of Launched and Acquired Products(1) ■Pipeline Momentum Builds on Positive Phase 3 and Mid-Stage Readouts ■Robust
Late‑Stage R&D Pipeline, On Track to Start ~20 Key Pivotal Studies in 2026 NEW YORK, Tuesday, May 5, 2026 — Pfizer Inc.
EVIDENCE AGAINST
• The comparable net loss changed -108.5% year over year; the company remained loss-making in the latest period.
BOTTOM LINE
The evidence is mixed rather than one-directional.
Official operating disclosure: EX-99 2 pfe-6282026xex99.htm EX-99 Document Exhibit 99 Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance ■Focused Execution Drove 18% Operational Revenue Growth of Launched and Acquired Products(1) ■Advancing Robust Late-Stage Pipeline, with Several Key Pivotal Readouts Expected Over Next 12 Months ■Announces Expansion of Productivity Enhancement Initiatives NEW YORK, Tuesday, August 4, 2026 — Pfizer Inc.
A key counterpoint: The comparable net loss changed -108.5% year over year; the company remained loss-making in the latest period. The thesis should be updated only when the measurable watch conditions change.
WHAT WOULD CHANGE THE VIEW
• Check whether the next filing confirms the direction of R&D expense after Q2 2026.
• Check whether the next filing confirms the direction of inventory after Q2 2026 period end.
• A daily close below the nearest support cluster around $26.47 would weaken the price structure.
• Holding above the nearest trend reference around $26.41 would preserve the constructive price structure.
PUBLIC SOURCES
• PFE latest comparable SEC filing (2026-08-04): https://data.sec.gov/api/xbrl/companyfacts/CIK0000078003.json
• PFIZER INC filed an 8-K with the SEC — Exhibit 99.1 earnings release (2026-08-04): https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-6282026xex99.htm
• PFIZER INC filed an 8-K with the SEC — Exhibit 99.1 earnings release (2026-05-05): https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/pfe-3292026xex99.htm
• PFIZER INC filed a 10-Q with the SEC (2026-08-04): https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/0000078003-26-000095-index.htm
• PFIZER INC filed a 10-Q with the SEC (2026-05-05): https://www.sec.gov/Archives/edgar/data/78003/000007800326000054/0000078003-26-000054-index.htm
#Stocks #Fundamentals #TechnicalAnalysis #PFE
PFIZER INC
CORE QUESTION
Can PFIZER INC's current revenue growth convert into earnings and cash flow before expectations outrun operating evidence? Sector-specific lens: Which regulatory, clinical or manufacturing milestone is the next measurable validation point?
WHAT CHANGED
• R&D expense year-over-year growth changed by +0.1 percentage points from the preceding reported quarter.
• Inventory year-over-year growth changed by -13.1 percentage points from the preceding reported quarter.
OPERATING EVIDENCE
• Revenue: $15.03B in Q2 2026; +2.6% YoY.
• Net income: $-248.00M in Q2 2026; -108.5% YoY.
• Diluted EPS: $-0.04 in Q2 2026; -107.8% YoY.
• R&D expense: $2.81B in Q2 2026; +13.2% YoY.
• Inventory: $9.95B in Q2 2026 period end; -14.8% YoY.
• Stock-based compensation: $272.00M in Q1 2026; +60.0% YoY.
EXPECTATIONS AND VALUATION
• trailing P/E 34.9x; forward P/E 9.2x; EV/EBITDA 8.1x; P/S 2.4x.
• Next-year Yahoo consensus snapshot for period ending 2027-12-31: EPS estimate $2.89 (25 analysts); revenue estimate $59.85B (25 analysts).
INSTITUTIONAL EVIDENCE
• 2026-07-08 — [COMPANY-SPECIFIC] Pfizer’s earnings guidance has room for an upward revision, but its pipeline remains the market’s focus (J.P. Morgan)
J.P. The report said Pfizer’s stock is currently valued at approximately 9 times projected 2027 earnings, making the valuation inexpensive, while several pipeline assets could add appeal to the long-term investment narrative.
However, the recent Phase 3 failure of sigvotatug vedotin in second-line or later non-small cell lung cancer represents a significant negative development and has reduced visibility into the development pipeline.
OFFICIAL COMPANY EVIDENCE
• 2026-08-04 — [SEC EXHIBIT 99.1] PFIZER INC filed an 8-K with the SEC — Exhibit 99.1 earnings release; reporting basis: mixed_reconciled.
• 2026-05-05 — [SEC EXHIBIT 99.1] PFIZER INC filed an 8-K with the SEC — Exhibit 99.1 earnings release; reporting basis: mixed_reconciled.
• 2026-08-04 — [SEC FILING NOTICE] PFIZER INC filed a 10-Q with the SEC.
• 2026-05-05 — [SEC FILING NOTICE] PFIZER INC filed a 10-Q with the SEC.
MARKET STRUCTURE
• Latest price $26.52; HMA21 $26.41; HMA55 $25.33; 200DMA $25.89.
EVIDENCE FOR
• Revenue changed +2.6% year over year in the latest comparable period.
• Price is above all three HMA21, HMA55 and 200DMA trend references.
• Forward P/E of 9.2x is below trailing P/E of 34.9x, implying expected earnings improvement.
• Official operating disclosure: EX-99 2 pfe-6282026xex99.htm EX-99 Document Exhibit 99 Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
■Focused Execution Drove 18% Operational Revenue Growth of Launched and Acquired Products(1) ■Advancing Robust Late-Stage Pipeline, with Several Key Pivotal Readouts
Expected Over Next 12 Months ■Announces Expansion of Productivity Enhancement Initiatives NEW YORK, Tuesday, August 4, 2026 — Pfizer Inc.
• Official operating disclosure: primarily due to pricing dynamics, including lower rebates and channel mix favorability, as well as higher demand globally; partially
offset by declines due to generic entry and price erosion in certain international markets; ■Padcev globally, up 23% operationally, driven primarily by increased market
share in first-line locally advanced or metastatic urothelial cancer (la/mUC), as well as launch uptake in the cisplatin-ineligible indication for muscle-invasive bladder
cancer; partially offset by a one-time favorable impact associated with transition to a wholesaler distribution model in the U
• Official operating disclosure: Phase 3 planning for atopic dermatitis is ongoing, with a pivotal study on track to start this year.
• Official operating disclosure: EX-99 2 pfe-3292026xex99.htm EX-99 Document Exhibit 99 g Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance ■Earnings
Driven by Focused Execution and 22% Op Revenue Growth of Launched and Acquired Products(1) ■Pipeline Momentum Builds on Positive Phase 3 and Mid-Stage Readouts ■Robust
Late‑Stage R&D Pipeline, On Track to Start ~20 Key Pivotal Studies in 2026 NEW YORK, Tuesday, May 5, 2026 — Pfizer Inc.
EVIDENCE AGAINST
• The comparable net loss changed -108.5% year over year; the company remained loss-making in the latest period.
BOTTOM LINE
The evidence is mixed rather than one-directional.
Official operating disclosure: EX-99 2 pfe-6282026xex99.htm EX-99 Document Exhibit 99 Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance ■Focused Execution Drove 18% Operational Revenue Growth of Launched and Acquired Products(1) ■Advancing Robust Late-Stage Pipeline, with Several Key Pivotal Readouts Expected Over Next 12 Months ■Announces Expansion of Productivity Enhancement Initiatives NEW YORK, Tuesday, August 4, 2026 — Pfizer Inc.
A key counterpoint: The comparable net loss changed -108.5% year over year; the company remained loss-making in the latest period. The thesis should be updated only when the measurable watch conditions change.
WHAT WOULD CHANGE THE VIEW
• Check whether the next filing confirms the direction of R&D expense after Q2 2026.
• Check whether the next filing confirms the direction of inventory after Q2 2026 period end.
• A daily close below the nearest support cluster around $26.47 would weaken the price structure.
• Holding above the nearest trend reference around $26.41 would preserve the constructive price structure.
PUBLIC SOURCES
• PFE latest comparable SEC filing (2026-08-04): https://data.sec.gov/api/xbrl/companyfacts/CIK0000078003.json
• PFIZER INC filed an 8-K with the SEC — Exhibit 99.1 earnings release (2026-08-04): https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-6282026xex99.htm
• PFIZER INC filed an 8-K with the SEC — Exhibit 99.1 earnings release (2026-05-05): https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/pfe-3292026xex99.htm
• PFIZER INC filed a 10-Q with the SEC (2026-08-04): https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/0000078003-26-000095-index.htm
• PFIZER INC filed a 10-Q with the SEC (2026-05-05): https://www.sec.gov/Archives/edgar/data/78003/000007800326000054/0000078003-26-000054-index.htm
#Stocks #Fundamentals #TechnicalAnalysis #PFE
Charts
Full text
PFE latest comparable SEC filing
Revenue YoY=2.6001501399030915; net income YoY=-108.52233676975945; EPS YoY=-107.84313725490198
Revenue YoY=2.6001501399030915; net income YoY=-108.52233676975945; EPS YoY=-107.84313725490198
PFE valuation snapshot
trailing_pe=34.901318; forward_pe=9.17401; enterprise_to_ebitda=8.126; price_to_sales=2.3735218
trailing_pe=34.901318; forward_pe=9.17401; enterprise_to_ebitda=8.126; price_to_sales=2.3735218
PFE Revenue
CY2026Q2: 15034000000.0; YoY=2.6001501399030915
CY2026Q2: 15034000000.0; YoY=2.6001501399030915
PFE Net income
CY2026Q2: -248000000.0; YoY=-108.52233676975945
CY2026Q2: -248000000.0; YoY=-108.52233676975945
PFE Diluted EPS
CY2026Q2: -0.04; YoY=-107.84313725490198
CY2026Q2: -0.04; YoY=-107.84313725490198
PFE R&D expense
CY2026Q2: 2809000000.0; YoY=13.174858984689767
CY2026Q2: 2809000000.0; YoY=13.174858984689767
PFE Inventory
CY2026Q2I: 9945000000.0; YoY=-14.77418801953895
CY2026Q2I: 9945000000.0; YoY=-14.77418801953895
PFE Stock-based compensation
CY2026Q1: 272000000.0; YoY=60.0
CY2026Q1: 272000000.0; YoY=60.0
Pfizer’s earnings guidance has room for an upward revision, but its pipeline remains the market’s focus (J.P. Morgan)
J.P. The report said Pfizer’s stock is currently valued at approximately 9 times projected 2027 earnings, making the valuation inexpensive, while several pipeline assets could add appeal to the long-term investment narrative. However, the recent Phase 3 failure of sigvotatug vedotin in second-line or later non-small cell lung cancer represents a significant negative development and has reduced visibility into the development pipeline.
J.P. The report said Pfizer’s stock is currently valued at approximately 9 times projected 2027 earnings, making the valuation inexpensive, while several pipeline assets could add appeal to the long-term investment narrative. However, the recent Phase 3 failure of sigvotatug vedotin in second-line or later non-small cell lung cancer represents a significant negative development and has reduced visibility into the development pipeline.
PFIZER INC filed an 8-K with the SEC — Exhibit 99.1 earnings release
EX-99 2 pfe-6282026xex99.htm EX-99 Document Exhibit 99 Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance ■Focused Execution Drove 18% Operational Revenue Growth of Launched and Acquired Products(1) ■Advancing Robust Late-Stage Pipeline, with Several Key Pivotal Readouts Expected Over Next 12 Months ■Announces Expansion of Productivity Enhancement Initiatives NEW YORK, Tuesday, August 4, 2026 — Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026 and raised its full-year 2026 Revenue guidance by $500 million at the midpoint while reaffirming guidance(2) for Adjusted(3) diluted EPS, which absorbs an impact of approximately $0.10 related to the Innovent Biologics, Inc. transaction. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “Pfizer had another strong quarter, delivering on our financial commitments and advancing our strategy. Our launched and acquired products(1) performed well, our obesity program is advancing with meaningful momentum and our oncology portfolio remains a source of strength. I am confident we will create substantial future value for patients and shareholders.” Cecile Guegan, Incomin
EX-99 2 pfe-6282026xex99.htm EX-99 Document Exhibit 99 Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance ■Focused Execution Drove 18% Operational Revenue Growth of Launched and Acquired Products(1) ■Advancing Robust Late-Stage Pipeline, with Several Key Pivotal Readouts Expected Over Next 12 Months ■Announces Expansion of Productivity Enhancement Initiatives NEW YORK, Tuesday, August 4, 2026 — Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026 and raised its full-year 2026 Revenue guidance by $500 million at the midpoint while reaffirming guidance(2) for Adjusted(3) diluted EPS, which absorbs an impact of approximately $0.10 related to the Innovent Biologics, Inc. transaction. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “Pfizer had another strong quarter, delivering on our financial commitments and advancing our strategy. Our launched and acquired products(1) performed well, our obesity program is advancing with meaningful momentum and our oncology portfolio remains a source of strength. I am confident we will create substantial future value for patients and shareholders.” Cecile Guegan, Incoming Interim CFO and EVP of Pfizer: “Our second-quarter results are attributable to our solid commercial performance globally as well as our ongoing focus on operational efficiency. This quarter, I’m particularly pleased with the 18% year-over-year operational revenue growth from our launched and acquired products(1). Our updated full-year 2026 guidance reflects the continued strength of and confidence in our business.” OVERALL RESULTS ■Second-Quarter 2026 Revenues of $15.0 Billion, Representing 1% Year-over-Year Operational Growth –Excluding Contributions from Comirnaty and Pax…
PFIZER INC filed an 8-K with the SEC — Exhibit 99.1 earnings release
EX-99 2 pfe-3292026xex99.htm EX-99 Document Exhibit 99 g Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance ■Earnings Driven by Focused Execution and 22% Op Revenue Growth of Launched and Acquired Products(1) ■Pipeline Momentum Builds on Positive Phase 3 and Mid-Stage Readouts ■Robust Late‑Stage R&D Pipeline, On Track to Start ~20 Key Pivotal Studies in 2026 NEW YORK, Tuesday, May 5, 2026 — Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2026 and reaffirmed its full-year 2026 financial guidance(2). EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “We're off to a strong start in 2026, and it reinforces our confidence that we will successfully navigate this defining period for Pfizer. Our R&D pipeline is advancing on multiple fronts – with positive Phase 3 readouts and encouraging mid-stage results building meaningful momentum – and I'm particularly encouraged by what we're seeing in oncology and obesity, two areas where I believe Pfizer is positioned to lead.” David Denton, CFO and EVP of Pfizer: “Our first-quarter results are attributable to our solid commercial performance globally as well as our ongoing focus on
EX-99 2 pfe-3292026xex99.htm EX-99 Document Exhibit 99 g Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance ■Earnings Driven by Focused Execution and 22% Op Revenue Growth of Launched and Acquired Products(1) ■Pipeline Momentum Builds on Positive Phase 3 and Mid-Stage Readouts ■Robust Late‑Stage R&D Pipeline, On Track to Start ~20 Key Pivotal Studies in 2026 NEW YORK, Tuesday, May 5, 2026 — Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2026 and reaffirmed its full-year 2026 financial guidance(2). EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “We're off to a strong start in 2026, and it reinforces our confidence that we will successfully navigate this defining period for Pfizer. Our R&D pipeline is advancing on multiple fronts – with positive Phase 3 readouts and encouraging mid-stage results building meaningful momentum – and I'm particularly encouraged by what we're seeing in oncology and obesity, two areas where I believe Pfizer is positioned to lead.” David Denton, CFO and EVP of Pfizer: “Our first-quarter results are attributable to our solid commercial performance globally as well as our ongoing focus on operational efficiency. This quarter, I’m particularly pleased with the 22% year-over-year operational revenue growth from our launched and acquired products(1). Today, we are reaffirming our full-year 2026 financial guidance.” OVERALL RESULTS ■First-Quarter 2026 Revenues of $14.5 Billion, Representing 2% Year-over-Year Operational Growth –Excluding Contributions from Comirnaty and Paxlovid, Revenues Grew 7% Operationally –Revenues of Launched and Acquired Products(1) Grew 22% Operationally ■First-Quarter 2026 Reported(3) Diluted EPS of $0.47, and Adjusted(4) Diluted EPS o…